UPDATE 1-U.S. judge rejects Amgen bid to block biosimilar Neupogen
March 19, 2015 at 15:55 PM EDT
SAN FRANCISCO, March 19 (Reuters) - A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients.
